Deprescribing of proton pump inhibitors in internal medicine in-patients: A retrospective observational study

Proton pump inhibitors (PPI) treat gastrointestinal disorders and are often overprescribed or continued unnecessarily, despite potential long-term adverse effects (e.g. infections). Deprescribing is recommended when indications are unclear or treatment unnecessarily prolonged. In Switzerland, national guidelines on PPI deprescribing are lacking. This study assessed PPI deprescribing frequency, appropriate new prescriptions and possible reasons for not performing deprescribing. Retrospective study at the Inselspital, Bern, Switzerland. Included were patients ≥18 years admitted to internal medicine wards during January–February 2022 with PPI on admission or newly prescribed during hospitalization. PPI duration and indication were retrieved from electronic health records. Data were evaluated with descriptive statistics and multivariable regression models. Among 852 admissions, 54% ( n = 458) were included (38% female, 72% ≥60 years old). Of them, 70% ( n = 320) had PPI on admission and 30% ( n = 138) newly prescribed during hospitalization, with appropriate use in 48% (153/320) and 49% (68/138) cases, respectively. At discharge, 376 (82%) of the included cases had PPI, 44% ( n = 166) with appropriate use. Among 300 patients with indicated deprescribing, this occurred in 90 (30%) and was less likely with PPI on admission (OR = 0.2, 95%CI:0.1–0.4, p < 0.01). Possible reasons for not performing deprescribing ( n = 210) included unmet bleeding prophylaxis criteria (61%, n = 128), unclear re-evaluation plans (8%, n = 17) and outdated indications (7%, n = 15). Most PPI were continued upon discharge, despite half lacking a clearly appropriate use. Knowledge, communication and information gaps may have contributed to missed deprescribing opportunities. Regular medication reviews across healthcare settings could improve deprescribing practices and ensure appropriate PPI use. • More than half of the cases lacked a clear proton pump inhibitor (PPI) indication • Nearly all continued the PPI during hospitalization and at discharge • Deprescribing was less likely in patients already admitted with a PPI

Authors

Institutions

Publication Details

Journal
Exploratory Research in Clinical and Social Pharmacy
Published
2026-05-01
DOI
https://doi.org/10.1016/j.rcsop.2026.100796
Primary Topic
Gastroesophageal reflux and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Deprescribing of proton pump inhibitors in internal medicine in-patients: A retrospective observational study

Leonie D Schreck, Manuel Haschke, Evangelia Liakoni, Carole Elodie Aubert et al.
Exploratory Research in Clinical and Social Pharmacy
Gastroesophageal reflux and treatments
article

Deprescribing of proton pump inhibitors in internal medicine in-patients: A retrospective observational study

Leonie D Schreck, Manuel Haschke, Evangelia Liakoni, Carole Elodie Aubert, Arani Anandarathakrishnan, Carla Meyer-Massetti, Christina Kotoula
article en

Abstract

Proton pump inhibitors (PPI) treat gastrointestinal disorders and are often overprescribed or continued unnecessarily, despite potential long-term adverse effects (e.g. infections). Deprescribing is recommended when indications are unclear or treatment unnecessarily prolonged. In Switzerland, national guidelines on PPI deprescribing are lacking. This study assessed PPI deprescribing frequency, appropriate new prescriptions and possible reasons for not performing deprescribing. Retrospective study at the Inselspital, Bern, Switzerland. Included were patients ≥18 years admitted to internal medicine wards during January–February 2022 with PPI on admission or newly prescribed during hospitalization. PPI duration and indication were retrieved from electronic health records. Data were evaluated with descriptive statistics and multivariable regression models. Among 852 admissions, 54% ( n = 458) were included (38% female, 72% ≥60 years old). Of them, 70% ( n = 320) had PPI on admission and 30% ( n = 138) newly prescribed during hospitalization, with appropriate use in 48% (153/320) and 49% (68/138) cases, respectively. At discharge, 376 (82%) of the included cases had PPI, 44% ( n = 166) with appropriate use. Among 300 patients with indicated deprescribing, this occurred in 90 (30%) and was less likely with PPI on admission (OR = 0.2, 95%CI:0.1–0.4, p < 0.01). Possible reasons for not performing deprescribing ( n = 210) included unmet bleeding prophylaxis criteria (61%, n = 128), unclear re-evaluation plans (8%, n = 17) and outdated indications (7%, n = 15). Most PPI were continued upon discharge, despite half lacking a clearly appropriate use. Knowledge, communication and information gaps may have contributed to missed deprescribing opportunities. Regular medication reviews across healthcare settings could improve deprescribing practices and ensure appropriate PPI use. • More than half of the cases lacked a clear proton pump inhibitor (PPI) indication • Nearly all continued the PPI during hospitalization and at discharge • Deprescribing was less likely in patients already admitted with a PPI

Exploratory Research in Clinical and Social Pharmacy
University of Bern (CH), University Hospital of Bern (CH)
Openalex Percentile: Top 4%
Gastroesophageal reflux and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.